Drug focus: adalimumab in the treatment of moderate to severe psoriasis.
Adalimumab is a fully human IgG1 monoclonal antibody that specifically binds to tumor necrosis factor (TNF)-alpha, and is administered by subcutaneous injection. The mechanism of action is based on both the neutralization of TNF-alpha bioactivity and the induction of apoptosis of TNF-expressing mononuclear cells. The drug is approved for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis (PsA), and recently also for the treatment of Crohn's disease. The effectiveness of adalimumab in psoriasis was previously suggested by the subset analysis of patients enrolled in PsA trials who were affected by concomitant psoriasis, and recently confirmed by a phase II trial and the preliminary results from phase III trials in moderate to severe psoriasis. These results demonstrate that adalimumab is effective in improving psoriasis and quality of life, with sustained effects over >/= 1-year treatment period. The safety data from psoriasis studies were similar to those of previous studies in other diseases. The risk of adverse events did not appear to increase with continuous long-term exposure to adalimumab.
Vena
Gino A
GA
2nd Dermatology Clinic, University of Bari, Italy.
Cassano
Nicoletta
N
Arthritis Rheum. 2006 Dec;54(12):3782-9
17133559
Clin Ther. 2006 Oct;28(10):1619-29
17157117
Rheumatol Int. 2007 Jan;27(3):269-74
17006705
Clin Exp Dermatol. 2007 Jan;32(1):18-22
17305904
Arch Dermatol. 2007 Feb;143(2):233-6
17310003
Ann Rheum Dis. 2005 Mar;64 Suppl 2:ii14-7
15708927
Semin Arthritis Rheum. 2005 Apr;34(5 Suppl1):19-22
15852250
Clin Dermatol. 2003 Sep-Oct;21(5):392-7
14678719
Inflamm Bowel Dis. 2006 Jan;12(1):22-8
16374254
Aliment Pharmacol Ther. 2005 Feb 1;21(3):251-8
15691299
J Rheumatol. 2007 Feb;34(2):272-9
17304653
Ann Rheum Dis. 2007 Feb;66(2):163-8
17046964
J Am Acad Dermatol. 2006 Oct;55(4):598-606
17010738
J Am Acad Dermatol. 2005 Mar;52(3 Pt 1):434-44
15761421
J Eur Acad Dermatol Venereol. 2006 Apr;20(4):370-9
16643132
Arch Dermatol. 2007 Feb;143(2):223-31
17310002
Am J Clin Dermatol. 2005;6(6):383-92
16343026
Ann Rheum Dis. 2004 May;63(5):508-16
15082480
Best Pract Res Clin Rheumatol. 2006 Aug;20(4):757-90
16979537
Expert Opin Drug Saf. 2005 Jul;4(4):637-41
16011443
Dermatology. 2006;212(2):137-44
16484820
Arthritis Rheum. 2005 Oct;52(10):3279-89
16200601
Br J Dermatol. 2005 Nov;153(5):945-53
16225604
Clin Exp Dermatol. 1994 May;19(3):210-6
8033378
Dermatologica. 1978;157(4):238-44
357213
Am J Gastroenterol. 2004 Oct;99(10):1984-9
15447761
Arthritis Rheum. 2007 Feb;56(2):476-88
17265483
J Eur Acad Dermatol Venereol. 2006 Sep;20(8):921-5
16922938
J Am Acad Dermatol. 2006 Mar;54(3 Suppl 2):S67-80
16488332
J Rheumatol. 2007 Feb;34(2):380-5
17013997
Br J Dermatol. 2004 Dec;151(6):1219-26
15606518
Expert Opin Biol Ther. 2005 Nov;5(11):1491-504
16255652
Aliment Pharmacol Ther. 2006 Feb 15;23(4):451-63
16441465
J Am Acad Dermatol. 2005 Jan;52(1):140-1
15627096
Manag Care Interface. 2006 Apr;19(4):20-6
16689023
Clin Exp Dermatol. 2007 Mar;32(2):176-9
17176269
Ann Rheum Dis. 2006 Jul;65(7):889-94
16439435
J Pharmacol Exp Ther. 2005 May;313(2):578-85
15647331
Br J Dermatol. 2005 Sep;153(3):486-97
16120132
Ann Rheum Dis. 2007 Jul;66(7):921-6
17301106
Scand J Rheumatol. 2005 Sep-Oct;34(5):353-8
16234182